Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
Reference to Potential SRA737 Clinical Development Timeline in Sierra Oncology Investor Presentation at 2021 Cantor Virtual Global Healthcare Conference
Cambridge, UK, 29 September 2021 - Sareum Holdings plc (AIM: SAR), the specialist drug development company, notes that Sierra Oncology, the licence holder for SRA737 (a novel Chk1 inhibitor), presented at 21.00 BST on 28 September at the 2021 Cantor Virtual Global Healthcare Conference in a Fireside Chat. During this conference and included in a slide of recent and upcoming milestones, Sierra Oncology's CEO, Stephen Dilly, referred to the initiation of additional clinical studies with pipeline agents including SRA737 in other haematologic and solid tumour indications in the first half of 2022.
Specifically, reference was made to a potential role for SRA737 in combination studies in solid tumours, including pancreatic cancer, where patients have become resistant to PARP inhibitors.
In a previous discussion, noted by Sareum on 6 August 2021, of the rationale for in-licensing BET inhibitor AZD5153, now known as SRA515, from AstraZeneca, Sierra referred to possible pipeline expansion opportunities in other haematologic or solid tumour indications. These included potential combinations with SRA737, immune-oncology agents, PARP inhibitors and drugs with other mechanisms of action. Sierra has also noted that SRA515 has shown preclinical efficacy in combination with a diverse range of agents, and that synergy between SRA515 and a family of DNA damage response agents, known as ATR inhibitors, suggested potential utility in combination with SRA737.
SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed to Sierra in September 2016.
Sareum's CEO, Dr Tim Mitchell, commented:
"This timeline for the possible initiation of combination studies by Sierra including SRA737 in the first half of 2022 is very encouraging and would represent a significant advance in the development of the SRA737 programme. We look forward to further updates on the clinical development of SRA737, a molecule that has shown great promise in clinical trials and preclinical studies, particularly in combination with other types of cancer therapy."
…the next household name? Like GSK. Pfizer. AZ. Bayer?
Or will they swallow us up first?
Personally? I want SAREUM to be the name on everyone’s lips in years to come, and be like when Forrest Gump invested in “some fruit company”.
But that’s the reality big pharma is facing now…consume or be consumed…
Time will tell. Tick tick.
Ignore it silver.
Mad people think MMs communicate by making small trades (as low as single shares) to signal activity like “news coming” or “bring it down”
It’s all BS. Maybe back in the 90s but not today.
If I had a penny for every time someone calls out a “signal” and nothing happened I’d be an HNWI
Fizzy, fair play for trading this I wish I had the confidence when we know news could drop at any moment. I'm less confident this will go sub 5.
As for the "30 40 50 bags are why HNWI's invest" i keep seeing. What utter tosh. YES, they are clever investors, YES they will have done very thorough DD before investing such large figures. YES they will expect a return. NO they will not expect £50 million back. Don't be silly. If they get 50% back, that's £500k profit; i think even a HNWI would be happy with £500k for fairly minor work.
Guys, girls, and everything in between...
Markets are down.
Nothing has changed. You can't expect news and 20% days every week. If you do, you shouldn't be investing in anything other than crypto.
Apple shares lost 20% between the end of Jan and early March - APPLE ffs. This is the stock market. People get bored, lose confidence, have cash calls, chase other rainbows and sell up. And that's just internal factors.
We have a good thing going, but nothing is guaranteed in life. If you have lost your bottle, might be best to leave.
Genuinely thanks Mafuta for the helpful information - I never saw that as I’m on mobile.
Zylo there is no need for a sarcastic answer, thanks. I know they have to be RNSd but in actual fact the latest dealings were under a deferred salary RNS hence why I didn’t spot them. Now who looks silly?
I’m being slightly lazy here, although have glanced through RNSs since 2019 but can’t seem any related to director buys/sells.
Anyone know/have access to the tools as to when directors last bought or sold and current holdings?
No ulterior motive by the way, I’m just not aware of their position. Also given directors can’t buy or sell close to big news…
WIP,
LSE (free) is behind by 15 mins :) So true close won't be shown until 16:45 - unless there is a UT or PME. Google I believe shows the last trade.
I use the investing.com app (or website) for live prices which is free. Be warned, the first few minutes of trading the % up or down is always a bit haywire.
Are we all thinking today could be day 1 of 5 closing above 9p? Then hopefully by Monday we will have had 5 closes above 9p, HNWI exercises warrants and £5m fully raised. Agile if we want…
Or another HNWI in the mean time tops us up. Who cares, this is exciting either way!
HBD.
I hope he’s not referring to the “medical medium” scam…
https://www.bbc.com/news/blogs-trending-49763144